Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
CERo Therapeutics Holdings, Inc. - Common Stock
(NQ:
CERO
)
0.1459
-0.0021 (-1.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about CERo Therapeutics Holdings, Inc. - Common Stock
CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024
July 08, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
June 13, 2024
CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that
Via
PressReach
Exposures
Product Safety
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
June 13, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy
June 06, 2024
Disseminated on behalf of CERo Therapeutics Holdings. Cancer treatments have come a long way over the years, but there is a newer treatment that is providing even stage four cancer patients with a new...
Via
PressReach
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
June 06, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
May 15, 2024
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
March 07, 2024
From
CERo Therapeutics Holdings, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.